Top

American Journal of Cardiovascular Drugs

Published in:

30-04-2024 | Infection of the Genital Organs | Original Research Article

Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study

Authors: Munaza Riaz, Jingchuan Guo, Steven M. Smith, Eric A. Dietrich, David E. Winchester, Haesuk Park

Published in: American Journal of Cardiovascular Drugs | Issue 3/2024

Abstract

Purpose

The American Heart Association recommended sodium-glucose cotransporter-2 inhibitors (SGLT2i) for the management of heart failure with preserved ejection fraction (HFpEF). However, little is known about their real-world in-class comparative safety in patients with HFpEF. We aimed to assess the comparative safety of SGLT2i in the risk of urinary tract infection (UTI) or genital infection separately or as a composite outcome among patients with HFpEF.

Methods

This cohort study using MarketScan^® Commercial and Medicare supplemental databases (2012–2020) included patients aged ≥ 18 years with a diagnosis of HFpEF who initiated SGLT2i therapy. Three pairwise comparison groups were established: cohort 1, dapagliflozin versus canagliflozin; cohort 2, empagliflozin versus canagliflozin; and cohort 3, dapagliflozin versus empagliflozin. After stabilized inverse probability treatment weighting, Cox proportional hazards regression was used to compare the risk of UTI or genital infection separately or as a composite outcome in each cohort.

Results

The risk of the composite outcome did not significantly differ between canagliflozin and dapagliflozin (adjusted hazard ratio [aHR] 0.64; 95% confidence interval [CI] 0.36–1.14) or between empagliflozin and canagliflozin (aHR 1.25; 95% CI 0.77–2.05). Similarly, there was no evidence of difference between dapagliflozin and empagliflozin in this risk (aHR 0.76; 95% CI 0.48–1.21). The results of analyses separately assessing UTI or genital infection were similar.

Conclusions

There was no significant difference in the risk of UTI or genital infection among patients with HFpEF who initiated canagliflozin, dapagliflozin, or empagliflozin.

Available only for authorised users

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. https://doi.org/10.1056/NEJMoa2107038.CrossRefPubMed

Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2206286.CrossRefPubMed

Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022. https://doi.org/10.1161/CIR.0000000000001063.CrossRefPubMedPubMedCentral

JARDIANCE® (empagliflozin) tablets, for oral use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204629s026lbl.pdf. Accessed 15 Sep 2023

FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious#:~:text=FDA Accessed 14 Sep 2023.

Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017;33(3):553–62. https://doi.org/10.1080/03007995.2016.1271780.CrossRefPubMed

Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2016;11(11): e0166125.CrossRefPubMedPubMedCentral

Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017. https://doi.org/10.1038/s41598-017-02733-w.CrossRefPubMedPubMedCentral

Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018;20(3):620–8. https://doi.org/10.1111/dom.13124.CrossRefPubMed

10.

Caparrotta TM, Greenhalgh AM, Osinski K, et al. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) EXPOSURE AND OUTCOMES IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW OF POPULATION-BASED OBSERVATIONAL STUDIES. Diabetes Ther. 2021;12(4):991–1028. https://doi.org/10.1007/s13300-021-01004-2.CrossRefPubMedPubMedCentral

11.

McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiology. 2021;6(2):148–58. https://doi.org/10.1001/jamacardio.2020.4511.CrossRefPubMed

12.

Younes AM, Salem M, Maraey A, et al. Safety outcomes of SGLT2i in the heart failure trials: a systematic review and Meta-analysis. Int J Cardiol. 2022;366:51–6. https://doi.org/10.1016/j.ijcard.2022.06.059.CrossRefPubMed

13.

Cao Y, Li P, Li Y, Han Y. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis. ESC Heart Fail. 2022;9(3):1942–53. https://doi.org/10.1002/ehf2.13905.CrossRefPubMedPubMedCentral

14.

Cohen SS, Roger VL, Weston SA, et al. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Perspect. 2020;8(6):1–8. https://doi.org/10.1002/prp2.676.CrossRef

15.

Sarayani A, Wang X, Thai TN, Albogami Y, Jeon N, Winterstein AG. Impact of the transition from ICD-9-CM to ICD-10-CM on the identification of pregnancy episodes in US Health Insurance Claims Data. Clin Epidemiol. 2020;12:1129–38. https://doi.org/10.2147/CLEP.S269400.CrossRefPubMedPubMedCentral

16.

Germanos G, Light P, Zoorob R, et al. Validating use of electronic health data to identify patients with urinary tract infections in outpatient settings. Antibiotics (Basel, Switzerland). 2020;9(9):536. https://doi.org/10.3390/antibiotics9090536.CrossRefPubMedPubMedCentral

17.

Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434–8. https://doi.org/10.1111/dom.13531.CrossRefPubMed

18.

Gong FF, Jelinek MV, Castro JM, et al. Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open heart. 2018;5(2):e000782–e000782. https://doi.org/10.1136/openhrt-2018-000782.CrossRefPubMedPubMedCentral

19.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–56. https://doi.org/10.7326/M18-3136.CrossRefPubMedPubMedCentral

20.

Caro MKC, Cunanan EC, Kho SA. Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study. Diabetes Epidemiol Manag. 2022;7: 100082. https://doi.org/10.1016/j.deman.2022.100082.CrossRef

21.

Riaz M, Smith SM, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction. Pharmacotherapy. 2023;43(10):1024–1031. https://doi.org/10.1002/phar.2853.

22.

Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–11. https://doi.org/10.1161/CIRCOUTCOMES.113.000359.CrossRefPubMedPubMedCentral

23.

Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines. 2022. https://doi.org/10.3390/medicines9120059.CrossRefPubMedPubMedCentral

24.

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632–44. https://doi.org/10.1016/j.jacbts.2020.02.004.CrossRefPubMedPubMedCentral

25.

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373–81. https://doi.org/10.1016/j.diabres.2013.12.052.CrossRefPubMed

26.

Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809–13. https://doi.org/10.1038/s41591-022-01703-8.CrossRefPubMedPubMedCentral

27.

Male circumcision. Pediatrics. 2012;130(3):e756-85. https://doi.org/10.1542/peds.2012-1990.

28.

Rayens E, Rayens MNK. Demographic and socioeconomic factors associated with fungal infection risk, United States, 2019. Emerg Infect Dis. 2022;28(10):1955–69.CrossRefPubMedPubMedCentral

Title: Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study
Authors: Munaza Riaz
Jingchuan Guo
Steven M. Smith
Eric A. Dietrich
David E. Winchester
Haesuk Park
Publication date: 30-04-2024
Publisher: Springer International Publishing
Keywords: Infection of the Genital Organs
Empagliflozin
Dapagliflozin
Canagliflozin
Urinary Tract Infection
Heart Failure
Published in: American Journal of Cardiovascular Drugs / Issue 3/2024
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-024-00648-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2024

Comment on: “Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis”

Cost–Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China

Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020

Authors’ Reply to Rangwala et al: “Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis”

Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany

Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page